Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

23.05 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 23.05
Bid (Size) 22.00 (1)
Ask (Size) 30.01 (1)
Prev. Close 23.05
Today's Range 23.05 - 23.05
52wk Range 11.51 - 26.33
Shares Outstanding 33,816,459
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress
Pharvaris NV (PHVS) reported a Q2 2025 loss of €0.83/share, missing estimates. Revenue was nil as R&D spend rose. Focus remains on Phase 3 trials for deucrictibant in HAE/AAE-C1INH, with key data... 
Via Chartmill
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire

Performance

YTD
+24.3%
+24.3%
1 Month
+14.6%
+14.6%
3 Month
+27.8%
+27.8%
6 Month
+54.7%
+54.7%
1 Year
+16.1%
+16.1%

More News

Read More
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Proposed Public Offering of Ordinary Shares
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Outlines 2025 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Host Virtual Investor Event on October 23, 2024
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
From Pharvaris N.V.
Via GlobeNewswire

Frequently Asked Questions

Is Pharvaris N.V. - Ordinary Shares publicly traded?
Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.
What exchange does Pharvaris N.V. - Ordinary Shares trade on?
Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?
The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market
What is the current price of Pharvaris N.V. - Ordinary Shares?
The current price of Pharvaris N.V. - Ordinary Shares is 23.05
When was Pharvaris N.V. - Ordinary Shares last traded?
The last trade of Pharvaris N.V. - Ordinary Shares was at 09/05/25 04:00 PM ET
What is the market capitalization of Pharvaris N.V. - Ordinary Shares?
The market capitalization of Pharvaris N.V. - Ordinary Shares is 779.47M
How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?
Pharvaris N.V. - Ordinary Shares has 779M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.